Petosemtamab

立即咨询

Petosemtamab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

2213450-26-9

MCLA 158

Petosemtamab (MCLA 158) 是一种抗 EGFR (K_d: 0.22 nM) 和抗LGR5(K_d: 0.86 nM) 单克隆抗体 (mAb)。Petosemtamab 导致 LGR5+ 癌细胞中的 EGFR 信号传导阻断和受体降解。Petosemtamab 可用于头颈部鳞状细胞癌 (HNSCC)、转移性结直肠癌 (CRC) 等实体瘤的研究。

生物活性

Petosemtamab (MCLA 158) is an anti-EGFR(K_d: 0.22 nM) and anti-LGR5(K_d: 0.86 nM) monoclonal antibody (mAb). Petosemtamab leads toEGFRsignaling blockade and receptor degradation in LGR5+cancercells. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectalcancer(CRC)^[1]^[2].

IC₅₀& Target^[2]

EGFR

0.22 nM (Kd)

LGR5

0.85 nM (Kd)

体外研究
(In Vitro)

MCLA-158 (1 μg/mL, 24 or 72 h) leads to EGFR degradation in EGFR+/LGR5+ colorectal cancer organoids^[2].

Western Blot Analysis^[2]

Cell Line:	P18T (KRAS WT), C55T (KRAS G12V) and C82N (normal) organoids
Concentration:	1 μg/mL
Incubation Time:	1, 6, 24, 72 h
Result:	Time-dependently degraded EGFR.

体内研究
(In Vivo)

MCLA-158 (25 mg/kg/week, i.v., for 6 weeks) leads to tumor regression in esophageal squamous, gastric adenocarcinoma and head & neck PDX models^[2].

Animal Model:	Esophageal squamous, gastric adenocarcinoma and head & neck PDX models^[2]
Dosage:	25 mg/kg/week
Administration:	Intravenous injection (i.v.) for 6 weeks.
Result:	Inhibited tumor growth.

CAS 号

2213450-26-9

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.